IL2RB and breast carcinoma: Risk score also predicted expression of several immune checkpoints, including PD1, PDL1, PDL2, TIM3, CD28, ICOS, IL2RB, and 41BB, in TNBC patients, and its predictive value in these patients was similar to that observed in the overall breast cancer patient cohort (Supplementary Figure 2C, 2D).